全文获取类型
收费全文 | 1371篇 |
免费 | 65篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 45篇 |
妇产科学 | 43篇 |
基础医学 | 133篇 |
口腔科学 | 58篇 |
临床医学 | 100篇 |
内科学 | 259篇 |
皮肤病学 | 22篇 |
神经病学 | 78篇 |
特种医学 | 42篇 |
外科学 | 305篇 |
综合类 | 54篇 |
一般理论 | 1篇 |
预防医学 | 51篇 |
眼科学 | 20篇 |
药学 | 66篇 |
中国医学 | 2篇 |
肿瘤学 | 154篇 |
出版年
2023年 | 13篇 |
2022年 | 33篇 |
2021年 | 35篇 |
2020年 | 22篇 |
2019年 | 33篇 |
2018年 | 47篇 |
2017年 | 42篇 |
2016年 | 24篇 |
2015年 | 32篇 |
2014年 | 48篇 |
2013年 | 65篇 |
2012年 | 96篇 |
2011年 | 112篇 |
2010年 | 64篇 |
2009年 | 73篇 |
2008年 | 85篇 |
2007年 | 92篇 |
2006年 | 76篇 |
2005年 | 73篇 |
2004年 | 76篇 |
2003年 | 60篇 |
2002年 | 44篇 |
2001年 | 17篇 |
2000年 | 25篇 |
1999年 | 23篇 |
1998年 | 11篇 |
1997年 | 13篇 |
1996年 | 8篇 |
1995年 | 3篇 |
1994年 | 2篇 |
1993年 | 6篇 |
1992年 | 12篇 |
1991年 | 5篇 |
1990年 | 14篇 |
1989年 | 6篇 |
1988年 | 9篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 6篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1968年 | 5篇 |
1967年 | 2篇 |
1966年 | 1篇 |
1965年 | 3篇 |
1938年 | 1篇 |
1937年 | 1篇 |
排序方式: 共有1456条查询结果,搜索用时 15 毫秒
1.
2.
Increased arterial stiffness in young normotensive patients with Turner syndrome: associations with vascular biomarkers
下载免费PDF全文
![点击此处可从《Clinical endocrinology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
3.
4.
Statutory reimbursement agencies as well as private insurers throughout member states of the Organization for Economic Cooperation and Development (OECD) reimburse the cost of medicines on the basis of criteria that include robust clinical evidence, budget impact analysis, and incremental cost effectiveness. The Centers for Medicare and Medicaid Services (CMS) in the US are no exception to this rule and are, in principle, seeking to maximize benefit for their Medicare enrollees, whilst ensuring reasonable drug outlays for the small number of drugs that they reimburse. This paper provides a retrospective analysis of the way two functionally equivalent drugs are treated for reimbursement purposes by the CMS; the period under consideration was 2001–3. The two drugs, epoetin-α and darbepoetin-α, are used for the treatment of anemia in renal failure and in patients receiving chemotherapy. By reviewing the publicly available pharmacological and clinical data of epoetin-α and darbepoetin-α, the paper confirms the two drugs’ functional equivalence, despite their structural differences. The implications of dose conversion ratios and costs to Medicare are subsequently explored. It is argued that the issue of dose equivalence between epoetin-α and darbepoetin-α has significant implications for patients, practitioners, and payors. A payor’s perspective is adopted in this respect, whereby clinical evidence and pricing data are used simultaneously. Based on the clinical evidence, a dose conversion ratio for epoetin-α:darbepoetin-α is established, which achieves a comparable clinical effect for the two drugs and this is set to be <254IU:1μg. The incremental costs to Medicare are calculated subsequently. The Average Wholesale Price and the Outpatient Prospective Payment System rule that Medicare uses to reimburse providers are used and suggest that treatment of cancer patients with chemotherapy-related anemia with epoetin-α would save Medicare an estimated $US600 million each year. Patients would also benefit significantly in terms of lower co-payments for epoetin-α. The evidence is supportive of the decision made by the CMS to reimburse the two drugs at the rate reflecting the achievement of comparable clinical effects and therefore reducing the pass-through payments for darbepoetin-α to zero for the 2002–3 fiscal year. 相似文献
5.
K Naito H Hisazumi A Saka T Nakamura S Kanda I Mikawa S Ejiri T Miyagi T Katsumi K Kitagawa 《Hinyokika kiyo. Acta urologica Japonica》1990,36(4):487-494
To evaluate the effect of UFT, a mixture of ftorafur and uracil in a ratio of 1:4, in preventing postoperative recurrence of bladder cancer, we performed a randomized controlled study with a non-medication group as control. UFT was given orally 400 mg a day for 6 months. Of 111 patients, 56 were given UFT and 55 were followed up without any medication. The non-recurrence rate in the group treated with UFT was 62.8% after 1 year and 36.3% after 2 years of follow up, and that of the control group was 45.7% and 39.5%, respectively. The rate of non-recurrence in the UFT group was significantly higher (p less than 0.05) than that of the control group during the period of follow up for 2 years. The incidence of side effects was 6.8% in UFT patients. These results indicate the clinical usefulness of prophylactic administration of UFT for bladder cancer patients. 相似文献
6.
Modern surgery for gastric cancer--Japanese perspective. 总被引:1,自引:0,他引:1
7.
8.
Bassam Alchi Arimasa Shirasaki Ichiei Narita Shinichi Nishi Mitsuhiro Ueno Takako Saeki Shoji Miyamura Fumitake Gejyo 《Hypertension research》2006,29(3):203-207
A 48-year-old man presented with malignant hypertension and massive proteinuria. Renal angiography showed complete obstruction of the left renal artery and 99mTc-mercaptoacetylglycine (MAG3) renography showed a nonfunctioning left kidney. Percutaneous transluminal renal angioplasty of the left renal artery was unsuccessful; hence, the patient underwent left nephrectomy because of uncontrolled hypertension and proteinuria. Histological examination of a right kidney specimen revealed lesions of focal segmental glomerulosclerosis with benign nephrosclerosis. In contrast, histology of the left kidney showed typical ischemic kidney with hypertrophy of arteriolar smooth muscle cells. The patient responded favorably to the nephrectomy, as his blood pressure and urinary protein dramatically decreased with no antihypertensive medication. This case illustrates the heterogeneous effect of the renin-angiotensin system on either kidney in patients with renovascular hypertension due to unilateral renal artery stenosis. 相似文献
9.
10.